Literature DB >> 32886864

Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?

Theocharis Koufakis1, Nikolaos Papanas2, George Dimitriadis3, Pantelis Zebekakis1, Kalliopi Kotsa1.   

Abstract

Year:  2020        PMID： 32886864     DOI： 10.1111/1753-0407.13105

Source DB:  PubMed          Journal:  J Diabetes        ISSN： 1753-0407            Impact factor:   4.006


× No keyword cloud information.
  3 in total

1.  Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Alexandra Katsimardou; Maria Toumpourleka; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-15       Impact factor: 3.738

Review 2.  Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.

Authors:  Manfred Hecking; Adnan Sharif; Kathrin Eller; Trond Jenssen
Journal:  Transpl Int       Date:  2020-11-28       Impact factor: 3.782

3.  Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

Authors:  Theocharis Koufakis; Omar G Mustafa; Vasilios Tsimihodimos; Ramzi A Ajjan; Kalliopi Kotsa
Journal:  Drugs       Date:  2021-07-07       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.